Jacobs Levy Equity Management, Inc Arcus Biosciences, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 465,304 shares of RCUS stock, worth $5.16 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
465,304Holding current value
$5.16 Million% of portfolio
0.03%Shares
9 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.2MCall Options Held
288KPut Options Held
138K-
Black Rock Inc. New York, NY9.76MShares$108 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.39MShares$59.8 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.52MShares$39.1 Million0.39% of portfolio
-
State Street Corp Boston, MA2.99MShares$33.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2MShares$22.2 Million0.07% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $801M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...